This report is concerned with the capacities of aciclovir to protect mice challenged intracerebrally with multiple lethal doses of type 1 herpes simplex virus and to control multiplication of this virus in the brain. With treatment initiated 12 h after inoculation and continued for 4 consecutive days, aciclovir administered subcutaneously in daily doses ranging from 40 to 100 mg/kg led to 21-day survival rates of from 33 to 73% and reduced virus titers by 1 to 1,h x 4 logs on postchallenge day 8. The therapeutic accomplishments of the 100-mg/kg doses of aciclovir were comparable to those of 1,000-mg/kg doses of vidarabine (9-,B-Darabinofuranosyladenine); however, as measured by impact on body weight, aciclovir was better tolerated than vidarabine at these similarly effective doses.
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Aciclovir [ACV; 9-(2-hydroxyethoxymethyl)-guanine, or acycloguanosine] has been introduced recently as a potent and selective antiviral agent against herpes simplex virus type 1 (HSV-1) and HSV-2 (6, 7, 9, 13, 16) . In vitro this compound also inhibits the multiplication ofvaricella zoster virus, cytomegalovirus, and B virus but has no effect on vaccinia virus, adenovirus type 5, and a range of ribonucleic acid viruses (16) . ACV penetrates infected cells to a greater degree than uninfected cells (6) . Once introduced into cells, it is converted to a monophosphate form by an HSV-specific thymidine kinase and eventually to a triphosphate form. ACV triphosphate then acts by inhibition of viral DNA polymerase. An additional selective advantage is that ACV triphosphate has a 30-foldgreater affinity for viral deoxyribonucleic acid polymerase than for cellular deoxyribonucleic acid polymerase in vitro (6, 7) . In the present study we evaluated the therapeutic efficacy of ACV for the herpes encephalitis by observing the capacities of ACV to protect mice inoculated intracerebrally with HSV-1 and to control the multiplication of this virus in the brain. More the survival rates and the mean survival time of mice that died. The brains of dead mice were removed and homogenized. The homogenates were centrifuged (2,000 rpm), the supernatant was inoculated onto green monkey kidney cell (CV-1; American Tisue Culture Collection, Rockville, Md.) monolayers, and the cytopathic effects were observed to confirm that the mice died of encephalitis.
Determination of the viral titers in brains. A total of 150 mice inoculated with HSV-1 were divided into six equal subgroups and treated similarly to those in the survival studies. Five animals from each subgroup were sacrificed on days 2, 4, 6, and 8 postinoculation. Mice dying during these periods were excluded from the experiment. The brains of live mice were aseptically removed, weighed, pooled, and washed in sterile normal saline. After removal of the surface membranes, they were finely minced with scissore, homogenized, and made into a 10% suspension with sterile Hanks balanced salt solution. The suspension was frozen and thawed three tines and centrifuged at 2,000 rpm for 5 min at 4°C. The supernatant was then serially diluted and assayed on green monkey kidney CV-1 monolayers by using an ordinary plaque technique (14) .
RESULTS
Survival rate and mean survival time. Within 12 days post-inoculation, all infected saline-treated mice were dead. The mean survival time was 6.9 days. ACV at doses of 100, 80, 60 and 40 mg/kg per day for 4 days yielded survival rates of 73, 60, 33, and 33%, respectively. The mean survival time of mice that died was also significantly increased by 100 and 80 mg of ACV per kg per day (to 13.5 and 11.2 days, respectively) compared with saline-treated controls (100% dead at 6.9 days). Administation of ara-A also significantly increased the survival rate ANTimICROB. AGENTS CHEMOTHER.
(80%) and mean survival time of mice that died (14.0 days), compared with the same control group. When ACV (100 mg/kg per day) or ara-A (1,000 mg/kg per day) was given to the salineinoculated mice for 4 days, no deaths occurred (Table 1) .
Concentration of virus in brains. Treatment with ACV or ara-A resulted in a notable reduction in the infectious virus from pooled brains (Fig. 1 ). ACV at a daily dose of 40 or 60 mg/kg reduced the rivus titers 11-to 20-fold compared with the saline-treated controls during the period from day 2 to day 8 post-inoculation. Higher doses of ACV (80 and 100 mg/kg) and vidarabine gradually decreased the level of virus in brains and resulted in virus titers approximately ½h x 4 to 5 logs less than the titers in the saline-treated control brains on day 8 post-inoculation.
Body weight of mice. The comparative effects of ACV and ara-A on the body weight of mice are indicated in Table 2 . ACV treatments of virus-inoculated mice resulted in a slight reduction of body weight by day 8 post-inoculation. However, the weight was recovered, and ACV-treated mice started to gain weight from day 10 post-inoculation. When the highest dose of ACV (100 mg/kg) was given to saline-inoculated mice, the growth was initially slower than that of the normal mice (saline-treated and saline-inoculated), but there was no sigificant difference in weight between these two groups from day 10 of the study (P < 0.2). Vidarabine treatments in virus-or saline-inoculated mice, at a dose of 1,000 mg/kg, led to a gradual decrease in weight by day 8 post-inoculation. Furthermore, the vidarabine-treated animals had not (15) . Trifluorothymidine (5-trifluoromethyl-2'-deoxyuridine) (4) and 5-ethyl-2'-deoxyuridine (5) if infected mice. Brain tissues uwere removed ACV, 0.5% iododeoxyuridine, and 3% vidarabine timal groups on days 2, 4, 6, and 8 po8t-ointments against an experimemtal HSV kera-"'on and assayed as de5crnbed in the text. titis in rabbits. ACV was significantly more acr: *, saline-treated, infected mice; 0, ACV, 40 tive tha iododeoxyuridine and vidarabine, pro-)er day; 0, ACV, 60 mg/kg per day; U, ACV, ducin more ra dhe and no significpro cgper day; A, ACV, 1OO mg/kg per day; n ducig more rapid healig and no ificant 4, 1,OrXmg/kg per day. toxicity (13). Kaufman et al. (9) reported that ACV administered parenterally was effective in treating herpetic iritis in rabbits and prevented d to their original weight by day 16 post-death from encephalitis.
tion.
A pilot study by Schaeffer et al. (16) indicated that ACV, administered orally in a dose of 100 mg/kg twice daily for 5 days, ificantly inencephalitis is one of the most frequent creased the survival rate and mean survival time ic, life-threatening viral infections of the of mice inoculated intracerebrally with HSV-1. n the United States today (11, 12) . Pri-Our present experiments were designed to evalttack of HSV, both HSV-1 and HSV-2, is uate the chemotherapeutic efficacy of ACV in cause of herpes encephalitis (10, 12) . against experimental HSV-1 encephalitis in er, a latent infection of HSV can possibly mice, with responses measured in terms of surherpetic involvement of the central nerv-vival rate, mean survival time, and virus titer in tem (10) . the brain. In addition, the efficacies of various ntly, considerable effort has been dedi-nontoxic doses of ACV were compared with the ;o treating HSV encephalitis. Systemic effectiveness of the maximum tolerated dose of with iododeoxyuridine for the treatment ara-A, a compound recently approved by the encephalitis was initially met with some Food and Drug Administration for use in herasm (3, 11) . Two placebo-controlled, dou-petic infections, including human herpetic end studies designed to evaluate the cephalitis. To determine the nontoxic level of herapeutic efficacy of iododeoxyuridine ACV, various doses of the agent were adminisencephalitis were, however, prematurely tered daily for 4 days to 20-g mice by two divided ted; iododeoxyuridine not only failed to doses through subcutaneous injection. Daily morbidity and mortality, but also caused doses of ACV up to 100 mg/kg for 4 days did not toxicity, namely myelosuppression (1). induce weight loss or other untoward reactions. )ine has been shown to be an effective Weight loss was significant at daily doses of 200 gainst HSV encephalitis in hamsters (17) , mg/kg for 4 days. The latter dose also effects a 18, 19) , and humans (2, 20, 21) . A pilot moderate reduction in number of Jerne hemoy Ch'ien et al. (2) In vitro antiviral activity of ACV was not determined. However, ACV has been reported to be 160 times more active than ara-A against HSV-1 in plaque reduction assays (16) . Doses of ara-A up to 1,000 mg/kg per day for 4 days were tolerated by mice. A dose of 2,000 mg/kg per day was lethal to more than 50% of the animals. Therefore, ara-A was used in a dose 1,000 mg/ kg per day in the current studies. This dosage has been shown to provide a 100% protection of weanling mice challenged intracerebrally with 10 50% lethal doses of HSV-1 (8).
The present studies have shown that ACV is highly effective against HSV-1 encephalitis in mice and that this activity, measured by increased survival rates or mean survival times, is dose dependent. ACV also diminished brain titers of HSV-1 in infected mice in a dose-dependent manner. Ara-A significantly increased survival rate and mean survival time and decreased brain virus titers in infected mice. However, ara-A, unlike ACV, caused a significant decrease in body weight in uninfected, saline-treated mice. Thus, ACV appears to be capable of fulfilling several important criteria for an effective antiviral agent: increased survival rate and survival time at an apparently nontoxic dose. On the basis of these observations, we believe that ACV clearly merits further investigation as a highly effective antiviral agent, not only for the treatment of herpes encephalitis but also as therapy for other manifestations of herpetic disease. 
